Drug Information

Drug General Information
Drug ID
D0C5XC
Former ID
DAP000322
Drug Name
Clemastine
Synonyms
Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
Drug Type
Small molecular drug
Indication Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] Approved [538250], [541312]
Therapeutic Class
Antiallergic Agents
Company
Norvatis Phamaceuticals Corporation
Structure
Download
2D MOL

3D MOL
Formula
C21H26ClNO
InChI
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
InChIKey
YNNUSGIPVFPVBX-NHCUHLMSSA-N
CAS Number
CAS 15686-51-8
PubChem Compound ID
26987
PubChem Substance ID
597386, 7978959, 8169501, 11111002, 11112618, 11114089, 11335460, 11360699, 11371365, 11374708, 11461671, 11466334, 11467454, 11484553, 11486227, 11488505, 11490169, 11492770, 14875878, 34669560, 46506492, 47216681, 47440147, 48035000, 48035001, 48035002, 48334381, 48334382, 48415792, 49698428, 50038481, 50297783, 85788464, 92308858, 92729734, 93166549, 96079549, 103605085, 104105756, 104298787, 117462440, 124882478, 135021180, 136018285, 137001887, 141654852, 152146162, 160963631, 162180590, 162224684
SuperDrug ATC ID
D04AA14; R06AA04
SuperDrug CAS ID
cas=015686518
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [536618], [536744]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 538250FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073283.
Ref 541312(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6063).
Ref 536618Stereoselective synthesis of (-)-hydroxyclemastine as a versatile intermediate for the H1 receptor antagonist clemastine. Arch Pharm Res. 2007 Dec;30(12):1521-5.
Ref 536744Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. Epub 2008 Jun 12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.